IHC marker panel expansion: 150+ antibodies

We are pleased to announce a significant expansion of our immunohistochemical marker panel. EPL Lab now offers over 150 antibodies for diagnosing a wide range of neoplasms.

New markers include: PD-L1 (clone 22C3 and SP263) for determining immunotherapy indications, NTRK for detecting fusion proteins, IDH1 R132H for gliomas, BRAF V600E for melanoma and colorectal cancer.

The expanded panel allows our partner clinics to receive the full scope of immunohistochemical diagnostics without the need to send material to foreign laboratories. This reduces the waiting time for results and the start of treatment.